Abstract
Some physiopathological processes involved in the genesis of diseases could suggest the necessity of designing bioligands or prototypes that aggregate, in only one molecule, dual pharmacodynamical properties, becoming able to be recognized by two elected bioreceptors. This approach can have distinct aspects and, when a novel ligand or a prototype acts in two elected targets belonging to the same biochemical pathway, e.g. arachidonic acid cascade, it receives the denomination of dual or mix agent. On the other hand, if these two targets belong to distinct biochemical routes and both are related to the same disease, we can characterize the agents able to modulate it as symbiotic ligands or prototypes. In the present work, we provide some examples and applications of the molecular hybridization concept for the structural design of new symbiotic ligands and prototypes, especially those applied in the treatment of chronic-degenerative disorders.
Keywords: Symbiotic drugs, molecular hybridization, multifactorial diseases, therapeutic innovation, drug design, dual compounds
Current Drug Therapy
Title: New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs
Volume: 3 Issue: 1
Author(s): Carlos Alberto Manssour Fraga and Eliezer J. Barreiro
Affiliation:
Keywords: Symbiotic drugs, molecular hybridization, multifactorial diseases, therapeutic innovation, drug design, dual compounds
Abstract: Some physiopathological processes involved in the genesis of diseases could suggest the necessity of designing bioligands or prototypes that aggregate, in only one molecule, dual pharmacodynamical properties, becoming able to be recognized by two elected bioreceptors. This approach can have distinct aspects and, when a novel ligand or a prototype acts in two elected targets belonging to the same biochemical pathway, e.g. arachidonic acid cascade, it receives the denomination of dual or mix agent. On the other hand, if these two targets belong to distinct biochemical routes and both are related to the same disease, we can characterize the agents able to modulate it as symbiotic ligands or prototypes. In the present work, we provide some examples and applications of the molecular hybridization concept for the structural design of new symbiotic ligands and prototypes, especially those applied in the treatment of chronic-degenerative disorders.
Export Options
About this article
Cite this article as:
Manssour Fraga Alberto Carlos and Barreiro J. Eliezer, New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs, Current Drug Therapy 2008; 3 (1) . https://dx.doi.org/10.2174/157488508783331225
| DOI https://dx.doi.org/10.2174/157488508783331225 |
Print ISSN 1574-8855 |
| Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prolonged Physiologic Doses of Corticosteroids for the Treatment of Severe Community Acquired Pneumonia
Current Respiratory Medicine Reviews Adipose Tissue and Bone Marrow as Sources for Cell-based Therapeutic Angiogenesis in Ischemic Tissues: Biological Foundation and Clinical Prospects for Age-related Vascular Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Merging Transport Data for Choroid Plexus with Blood-Brain Barrier to Model CNS Homeostasis and Disease More Effectively
CNS & Neurological Disorders - Drug Targets Cognitive Impairment in the Septic Brain
Current Neurovascular Research Circadian Rhythm in Cytokines Administration
Mini-Reviews in Medicinal Chemistry Preliminary X-Ray Crystallographic Studies of a Lys49-Phospholipase A2 Homologue from Bothrops pirajai Venom Complexed with p-Bromophenacyl Bromide and α-Tocopherol Inhibitors
Protein & Peptide Letters The Neuroprotective Effect of Ginkgo biloba Leaf Extract and its Possible Mechanism
Central Nervous System Agents in Medicinal Chemistry Developing Pharmacotherapies for Cannabis and Cocaine Use Disorders
Current Neuropharmacology Pharmacological Management of Type 2 Diabetes Mellitus: An Update
Current Diabetes Reviews Scope and Limitations of The Co-Drug Approach to Topical Drug Delivery
Current Pharmaceutical Design CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies
Current Cancer Drug Targets Analysis of Annulated Sea Snake Venom, Hydrophis Cyanocinctus, Using Liquid Chromatography and MALDI-TOF/TOF
Current Proteomics Cardiovascular Therapeutics Targets on the NO–sGC–cGMP Signaling Pathway: A Critical Overview
Current Drug Targets Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design Hypertension and Concurrent Arrhythmias
Current Pharmaceutical Design Adverse Drug Reactions Amongst Adult Patients Admitted in Lagos State University Teaching Hospital Lagos, Nigeria
Current Drug Safety Evaluating the Safety and Tolerability of Azilsartan Medoxomil Alone or in Combination With Chlorthalidone in the Management of Hypertension: A Systematic Review
Current Hypertension Reviews COXIBs, CINODs and H2S-Releasing NSAIDs: Current Perspectives in the Development of Safer Non Steroidal Anti-Inflammatory Drugs
Current Medicinal Chemistry Current Developments in the Therapeutic Potential of S-Nitrosoglutathione, an Endogenous NO-Donor Molecule
Current Pharmaceutical Biotechnology





